PL2430051T3 - Kompozycje zawierające przeciwciała do leczenia chorób związanych z komórkami B lub T CD5+ HLA-DR+ - Google Patents
Kompozycje zawierające przeciwciała do leczenia chorób związanych z komórkami B lub T CD5+ HLA-DR+Info
- Publication number
- PL2430051T3 PL2430051T3 PL10720014T PL10720014T PL2430051T3 PL 2430051 T3 PL2430051 T3 PL 2430051T3 PL 10720014 T PL10720014 T PL 10720014T PL 10720014 T PL10720014 T PL 10720014T PL 2430051 T3 PL2430051 T3 PL 2430051T3
- Authority
- PL
- Poland
- Prior art keywords
- hla
- treating
- compositions containing
- related diseases
- containing antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09305434 | 2009-05-14 | ||
EP10720014.9A EP2430051B1 (en) | 2009-05-14 | 2010-05-14 | Compositions containing antibodies for treating cd5+ hla-dr+ b or t cell related diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2430051T3 true PL2430051T3 (pl) | 2017-04-28 |
Family
ID=41055306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL10720014T PL2430051T3 (pl) | 2009-05-14 | 2010-05-14 | Kompozycje zawierające przeciwciała do leczenia chorób związanych z komórkami B lub T CD5+ HLA-DR+ |
Country Status (7)
Country | Link |
---|---|
US (1) | US8679500B2 (pl) |
EP (1) | EP2430051B1 (pl) |
DK (1) | DK2430051T3 (pl) |
ES (1) | ES2584916T3 (pl) |
PL (1) | PL2430051T3 (pl) |
PT (1) | PT2430051T (pl) |
WO (1) | WO2010145895A1 (pl) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014516046A (ja) * | 2011-05-26 | 2014-07-07 | フンダシオ・クリニック・ペル・ア・ラ・レセルカ・ビオメディカ | がん若しくは腫瘍の治療用の又はアジュバントとして使用される可溶性タンパク質cd5又はcd6 |
EP2543680A1 (en) | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Multispecific mutated antibody Fab fragments |
US11369663B2 (en) | 2016-06-07 | 2022-06-28 | Washington University | Detection of CD5 and methods and compositions for modulating CD5 |
JP2021522303A (ja) | 2018-05-03 | 2021-08-30 | ゲンマブ ビー.ブイ. | 抗体バリアントの組み合わせおよびその使用 |
JP2022514693A (ja) * | 2018-12-21 | 2022-02-14 | マルチチュード インコーポレーテッド | Muc18に特異的な抗体 |
MX2021012961A (es) | 2019-04-24 | 2021-11-25 | Heidelberg Pharma Res Gmbh | Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos. |
WO2020247872A1 (en) * | 2019-06-05 | 2020-12-10 | Magenta Therapeutics, Inc. | T-cell depleting therapies |
WO2021167952A2 (en) * | 2020-02-20 | 2021-08-26 | The Feinstein Institutes For Medical Research | Agonist antibodies against endoglin and uses thereof |
WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10162870A1 (de) * | 2001-12-20 | 2003-07-10 | Alexander Cherkasky | Fusionsproteinen gegen B-Zell-Tumoren |
EP1479760A1 (de) * | 2003-05-19 | 2004-11-24 | ProBioGen AG | Künstliches Immunorgan |
CA2599734C (en) * | 2005-03-03 | 2014-01-28 | Immunomedics, Inc. | Humanized l243 antibodies |
-
2010
- 2010-05-14 ES ES10720014.9T patent/ES2584916T3/es active Active
- 2010-05-14 DK DK10720014.9T patent/DK2430051T3/en active
- 2010-05-14 WO PCT/EP2010/056664 patent/WO2010145895A1/en active Application Filing
- 2010-05-14 US US13/320,097 patent/US8679500B2/en not_active Expired - Fee Related
- 2010-05-14 EP EP10720014.9A patent/EP2430051B1/en active Active
- 2010-05-14 PT PT107200149T patent/PT2430051T/pt unknown
- 2010-05-14 PL PL10720014T patent/PL2430051T3/pl unknown
Also Published As
Publication number | Publication date |
---|---|
EP2430051B1 (en) | 2016-03-23 |
EP2430051A1 (en) | 2012-03-21 |
DK2430051T3 (en) | 2016-07-04 |
US20120121598A1 (en) | 2012-05-17 |
ES2584916T3 (es) | 2016-09-30 |
PT2430051T (pt) | 2016-07-11 |
WO2010145895A1 (en) | 2010-12-23 |
US8679500B2 (en) | 2014-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1245344A1 (zh) | 用於長片段閱讀測序的方法和組合物 | |
IL255009A0 (en) | Preparations that cause the help of t cells | |
PT2430051T (pt) | Composições contendo anticorpos para tratar doenças relacionadas com células b ou t cd5+ hla- dr+ | |
PT2475352E (pt) | Composição contendo palmitoiletanolamida ultramicronizada | |
EP2430195A4 (en) | COMPOSITIONS AND METHODS FOR STORING BIOLOGICAL SAMPLES | |
ZA201109364B (en) | Stabilized protein compositions | |
ZA201203183B (en) | Sulfomethylsuccinates, process for making same and compositions containing same | |
IL216061A0 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
GB0905863D0 (en) | Novel composition | |
HRP20150761T1 (hr) | Postupak za proäśišä†avanje lipopeptida | |
IL214664A (en) | Compositions are useful for treating hair-related conditions | |
IL213990A0 (en) | Compositions for decontamination | |
EP2419446A4 (en) | HUMANIZED ANTIBODY COMPOSITIONS AND METHOD FOR BINDING LYSOPHOSPHACIDIC ACID | |
IL219470A0 (en) | Compositions containing fractalknie-binding proteins and uses thereof | |
IL216395A0 (en) | Prothrombic complex composition | |
GB2476226B (en) | Optimisation | |
SG10201408508YA (en) | Combination composition useful for treating cardiovascular diseases | |
EP2451982A4 (en) | COMPOSITIONS AND METHODS FOR MAMMALS AND USE THEREOF | |
GB0917736D0 (en) | Gel composition | |
EP2174956A4 (en) | COMPOSITIONS FOR ANTIFIBRINOLYSIS THERAPY | |
EP2421952A4 (en) | COMPOSITIONS FOR THE TRANSFECTION OF BIOMOLECULES IN CELLS | |
PL2503883T3 (pl) | Kompozycja dezynfekująca | |
GB0900582D0 (en) | Tropical composition | |
PL2263454T3 (pl) | Kompozycja uzdatniająca | |
EP2415482A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF METASTASIS |